left logo-english

Research Grant|Grants4Targets


It is our goal to provide innovative treatment options for diseases with high unmet medical need. By fostering collaborations with excellent academic groups and start-ups we aim to translate ideas from basic research into novel drugs. In order to further pool expertise and to join forces for mutual benefit, Bayer has initiated the Grants4Targets program to support collaborative research projects on novel molecular targets in Bayer's areas of interest. To promote the validation of novel target and biomarker ideas, we have set up a grant scheme and provide our expertise in drug discovery. We look forward to hearing about your innovative ideas!


What targets are we looking for in G4T?

According to our definition a “druggable” target is a nucleic acid or a protein (e.g. an enzyme, a receptor) whose activity can be modified by external drug stimuli. Drugs can be low molecular weight compounds or biologics such as antibodies or recombinant proteins. We are looking for novel molecular targets and disease related biomarkers in the fields of:



Heart & Vascular Diseases: Atrial Fibrillation, Stroke Prevention in Atrial Fibrillation, Chronic Heart Failure, Peripheral Artery Disease, Cardioprotective mechanisms
Gynecology: Endometriosis (incl. adenomyosis uteri/endometriosis interna), Uterine Fibroids (uterine leiomyoma) and Polycystic Ovary Syndrome (PCOS)
Kidney Diseases: Hypertensive Nephropathy, Diabetic Kidney Disease, Acute Kidney Injury, Chronic Allograft Nephropathy, Polycystic Kidney Disease
Oncology: Oncogenic signaling
Specialty Lung Diseases: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, COPD-Frequent Exacerbators, Chronic Cough, Pulmonary Hypertension
Hemostatic & Acute Organ Disorder: Acute Respiratory Distress Syndrome, DIC, SIRS, Acute Coronary Syndrome, Venous Thrombosis, Hemophilia A

How can I apply?

In addition to the submission tool, further detailed information about this program can be found at this website. After a comprehensive internal review process by Bayer HealthCare scientists, feedback will be provided within approximately eight weeks after submission deadline. To foster close collaborations Bayer HealthCare scientists are nominated as project partners to bring in their know-how on target validation and to provide tools such as compounds or models depending on the project.


What types of grants are we offering?

Support Grants €5,000-10,000

To further advance research on targets that are at a very early stage of discovery; fixed grant approval letter; IP rights remain with the applicant.

Focus Grants €10,000-125,000

For more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug discovery process; fixed grant approval letter; IP rights remain with the applicant.

Grant types do not need to be selected by the grant applicant. The decision on grant allocation is made at the sole and absolute discretion of Bayer HealthCare.
Successful projects supported by a grant may lead to further collaborations.
In addition to financial grants we offer our expertise, tools and/or technologies such as antibodies, tool compounds, biobank samples.